News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gilead Sciences, Inc. (GILD) Close To Dominating Second Multibillion Market With Solvadi


2/21/2014 8:29:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

It's rare enough for a biotech to succeed, and even rarer for a biotech to ultimately dominate a therapeutic area. But to do it twice? That's almost unheard of, and yet here we are with Gilead Sciences (NASDAQ: GILD ) . Building off of a $9 billion franchise in HIV, Gilead is set to become the leader in the emerging multibillion-dollar hepatitis C (HCV) market.

Help employers find you! Check out all the jobs and post your resume.

Read at News Release
Read at Forbes

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES